Chia Nan University of Pharmacy & Science Institutional Repository:Item 310902800/34871
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 18240/20438 (89%)
Visitors : 5457851      Online Users : 1282
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
    •  Adv. Search
    Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer Goto mobile version
    CNU IR > Offices > 456 >  Item 310902800/34871


    Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/34871


    Title: Case report: Heterogenous SMARCA4-deficient thoracic non-small cell lung carcinoma with various responses to nivolumab
    Authors: Lin, Yun-Tzu
    Li, Chien-Feng
    Wu, Hung-Chang
    Jan, Yi-Hua
    Kuo, Yu-Hsuan
    Contributors: Chi Mei Med Ctr, Dept Oncol
    Chi Mei Med Ctr, Dept Pathol
    Natl Sun Yat sen Univ, Inst Precis Med
    Chi Mei Med Ctr, Dept Med Res
    Natl Inst Canc Res, Natl Hlth Res Inst
    Chia Nan Univ, Coll Pharm & Sci
    ACT Genom Co Ltd
    , Kaohsiung, Taiwan
    Keywords: SMARCA4
    BRG1
    SWI
    SNF
    lung cancer
    non-small cell lung carcinoma
    check-point inhibitors
    nivolumab
    Date: 2023
    Issue Date: 2024-12-25 11:04:52 (UTC+8)
    Publisher: FRONTIERS MEDIA SA
    Abstract: SMARCA4-deficient non-small cell carcinoma is an aggressive neoplasm with poor outcome. Several studies have highlighted its immunochemistry, pathophysiology, and underlying mechanisms, but studies of its definite treatment are few. Here, we report on a 69-year-old male with heterogenous pathological presentations of SMARCA4-deficient non-small cell carcinoma. He initially presented with neck lymphadenopathies. Immunohistochemistry staining and genomic profiling confirmed the diagnosis of SMARCA4-deficient non-small cell carcinoma. The patient responded well to immune checkpoint inhibitors with nivolumab. However, new lesions with various pathological presentations and various responses to nivolumab appeared during the treatment course. The patient survived more than 3 years from the initial diagnosis. This case shows the efficacy of nivolumab to treat SMARCA4-deficient non-small cell lung carcinoma.
    Relation: Frontiers in Immunology, v.14, Article 1131448
    Appears in Collections:[Offices] 456

    Files in This Item:

    File Description SizeFormat
    index.html0KbHTML4View/Open


    All items in CNU IR are protected by copyright, with all rights reserved.

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback